Postmarketing Surveillance Study of the Efficacy and Safety of Phentermine in Patients with Obesity
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background: Obesity is a complex problem that is now considered a chronic metabolic disease. In Korea, phentermine has been widely used for the treatment of obesity in the primary care setting since 2004. However, there have been very few studies on the safety and efficacy of phentermine. To investigate the safety and efficacy of this drug, a postmarketing surveillance study was performed. Methods: A total of 795 patients with obesity (body mass index ≥ 25 kg/m2) were enrolled from 30 primary care centers in Korea from September 2006 to November 2007. Patients were examined to ascertain safety and efficacy at 4-, 8-, and 12-week intervals. The criterion for efficacy was defined as a weight loss ≥ 5% of body weight. Results: Of the 795 enrolled patients, 735 (92.5%) were evaluated in safety assessments and 711 (89.4%) was included in efficacy assessments. A total of 266 adverse events (AEs) were reported by 218 patients (30.6%), and no serious AEs were reported. Among 711 patients, 324 patients (45.6%) lost ≥ 5% of their body weight. The mean weight loss was 3.8 ± 4.0 kg. Conclusion: AEs are commonly associated with phentermine, even though phentermine is effective for weight loss and relatively well-tolerated.
Abstract
Background: Obesity is a complex problem that is now considered a chronic metabolic disease. In Korea, phentermine has been widely used for the treatment of obesity in the primary care setting since 2004. However, there have been very few studies on the safety and efficacy of phentermine. To investigate the safety and efficacy of this drug, a postmarketing surveillance study was performed. Methods: A total of 795 patients with obesity (body mass index ≥ 25 kg/m2) were enrolled from 30 primary care centers in Korea from September 2006 to November 2007. Patients were examined to ascertain safety and efficacy at 4-, 8-, and 12-week intervals. The criterion for efficacy was defined as a weight loss ≥ 5% of body weight. Results: Of the 795 enrolled patients, 735 (92.5%) were evaluated in safety assessments and 711 (89.4%) was included in efficacy assessments. A total of 266 adverse events (AEs) were reported by 218 patients (30.6%), and no serious AEs were reported. Among 711 patients, 324 patients (45.6%) lost ≥ 5% of their body weight. The mean weight loss was 3.8 ± 4.0 kg. Conclusion: AEs are commonly associated with phentermine, even though phentermine is effective for weight loss and relatively well-tolerated.
참고문헌 (17)
- Bray GA, "The metabolic syndrome and obesity" (2007), Humana Press
- Ioannides-Demos LL, "Safety of drug therapies used for weight loss and treatment of obesity", Drug Saf, 29, pp.277~302 (2006)
- World Health Organization, "The Asia-Pacific perspective: redefining obesity and its treatment" (2000), Health Communications Australia
- "Population projections for Korea" (1996)[URL]
- Kaplan LM, "Pharmacological therapies for obesity", Gastroenterol Clin North Am, 34, pp.91~104 (2005)
- Halford JC, "Pharmacological management of appetite expression in obesity", Nat Rev Endocrinol, 6, pp.255~269 (2010)
- Ioannides-Demos LL, "Pharmacotherapies for obesity: past, current, and future therapies", J Obes, 2011, pp.179674~ (2011)
- Alexander M, "Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis", Synapse, 56, pp.94~99 (2005)
- Cannistra LB, "Appetite-suppressing drugs and valvular heart disease", Cardiol Rev, 7, pp.356~361 (1999)
- Sachdev M, "Effect of fenfluramine-derivative diet pills on cardiac valves: a metaanalysis of observational studies", Am Heart J, 144, pp.1065~1073 (2002)
- 김범수, "비만 환자에서 펜디메트라진의 유효성 및 안전성 평가를 위한 시판후조사", Korean Journal of Health Promotion, 10(2), pp.97~103 (2010), 대한임상건강증진학회
- Choi CJ, "Doubleblind, parallel-group, placebo-controlled multi-center clinical trial for evaluating the efficacy and safety of phentermine hydrochloride in obese patients", Korean J Obes, 14, pp.155~162 (2005)
- 박혜순, "비만 환자에서 메실산시부트라민의 유효성 및 안전성 평가를 위한 염산시부트라민과의 이중맹검, 무작위배정, 다기관 공동, 비교 임상시험", 대한비만학회지, 17(2), pp.82~90 (2008), 대한비만학회
- 김경곤, "Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People", Yonsei Medical Journal, 47(5), pp.614~625 (2006), 연세대학교의과대학
- Kay JM., "Dietary pulmonary hypertension", Thorax, 49(Suppl), pp.S33~S38 (1994)
- Rostagno C, "Dilated cardiomyopathy associated with chronic consumption of phendimetrazine", Am Heart J, 131, pp.407~409 (1996)
- Kim YS, "Determinants of non-compliance with lipid-lowering therapy in hyperlipidemic patients", Pharmacoepidemiol Drug Saf, 11, pp.593~600 (2002)